BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 28603560)

  • 1. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
    Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
    Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.
    Mateen S; Raina K; Jain AK; Agarwal C; Chan D; Agarwal R
    Epigenetics; 2012 Oct; 7(10):1161-72. PubMed ID: 22965008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Zebularine in Comparison to and in Combination with Trichostatin A on CIP/KIP Family (p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2), DNMTs (DNMT1, DNMT3a, and DNMT3b), Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) Gene Expression, Cell Growth Inhibition and Apoptosis Induction in Colon Cancer LS 174T Cell Line.
    Sanaei M; Kavoosi F
    Asian Pac J Cancer Prev; 2020 Jul; 21(7):2131-2139. PubMed ID: 32711442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells.
    Mazzio EA; Soliman KF
    Cancer Genomics Proteomics; 2017 Jan; 14(1):17-33. PubMed ID: 28031235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YM155, a small molecule inhibitor of survivin expression, sensitizes cancer cells to hypericin-mediated photodynamic therapy.
    Gyurászová K; Mikeš J; Halaburková A; Jendželovský R; Fedoročko P
    Photochem Photobiol Sci; 2016 Jun; 15(6):812-21. PubMed ID: 27241169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism.
    Lin S; Lei K; Du W; Yang L; Shi H; Gao Y; Yin P; Liang X; Liu J
    Int J Biochem Cell Biol; 2016 Feb; 71():24-34. PubMed ID: 26673998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
    Emanuele S; Lauricella M; Tesoriere G
    Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
    Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
    Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
    Hauswald S; Duque-Afonso J; Wagner MM; Schertl FM; Lübbert M; Peschel C; Keller U; Licht T
    Clin Cancer Res; 2009 Jun; 15(11):3705-15. PubMed ID: 19458058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
    Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
    Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.
    Hsieh YJ; Hwu L; Chen YC; Ke CC; Chen FD; Wang HE; Lin KP; Yeh HH; Chang CW; Liu RS
    J Nucl Med; 2014 Apr; 55(4):678-85. PubMed ID: 24639460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
    Jazirehi AR
    Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
    Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP
    Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
    Egger G; Aparicio AM; Escobar SG; Jones PA
    Cancer Res; 2007 Jan; 67(1):346-53. PubMed ID: 17210717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target.
    Kawano Y; Nasu K; Li H; Tsuno A; Abe W; Takai N; Narahara H
    Hum Reprod; 2011 Sep; 26(9):2486-98. PubMed ID: 21715447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells.
    Takai N; Desmond JC; Kumagai T; Gui D; Said JW; Whittaker S; Miyakawa I; Koeffler HP
    Clin Cancer Res; 2004 Feb; 10(3):1141-9. PubMed ID: 14871994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.
    Blanquart C; François M; Charrier C; Bertrand P; Gregoire M
    Curr Cancer Drug Targets; 2011 Oct; 11(8):919-28. PubMed ID: 21762083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.
    Rokhlin OW; Glover RB; Guseva NV; Taghiyev AF; Kohlgraf KG; Cohen MB
    Mol Cancer Res; 2006 Feb; 4(2):113-23. PubMed ID: 16513842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.